The North American mitochondrial disease registry

Area of Science:

• Mitochondrial Medicine
• Rare Diseases
• Genetics

Background:

• The North American Mitochondrial Disease Consortium (NAMDC) is a network of 17 clinical centers dedicated to advancing translational research in mitochondrial diseases.
• Funded by the National Institutes of Health (NIH) and part of the Rare Disease Clinical Research Network (RDCRN), NAMDC aims to improve understanding and treatment of these conditions.

Purpose of the Study:

• To establish and utilize a comprehensive Mitochondrial Disease Clinical Registry and Biorepository for translational research.
• To define disease phenotypes and genotypes, collect natural history data, and identify outcome measures for mitochondrial disorders.
• To characterize the safety and efficacy of novel therapies and train future investigators in mitochondrial disease research.

Main Methods:

• Utilized a centralized, encrypted Clinical Registry database at Columbia University Medical Center.
• Established a mitochondrial disease biorepository collecting DNA, plasma, cell, and tissue samples with coded identifiers.
• Implemented a Fellowship Program for training senior postdoctoral fellows in clinical trial methodology and offered pilot grants for early-stage research.

Main Results:

• Confirmed the clinical and genetic heterogeneity of mitochondrial diseases through the NAMDC Registry.
• Enrolled over 1600 patients in the registry and established a biorepository at Mayo Clinic.
• Initiated eight clinical studies and trained six fellows who continue to contribute to mitochondrial disease research.

Conclusions:

• The NAMDC Patient Registry and Biorepository are crucial for facilitating research in mitochondrial diseases.
• This infrastructure accelerates progress in understanding the complex mechanisms and developing effective treatments for mitochondrial disorders.